It is important to note, that blocking the IL-17 pathway is linked with adverse outcomes such as injection site reactions and upper respiratory infections given the role of the IL-17 axis in mucosal immunity against bacterial and fungal infections (161). The gene discussed is IL17A; the disease is respiratory tract infectious disorder.